Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have announced a research collaboration to develop ophthalmic formulations for corneal and ocular surface diseases, combining proprietary drug delivery technology with clinical research expertise.

• Technology: Utilises Formosa’s Active Pharmaceutical Nanoparticle Technology (APNT®) to reduce particle size of active ingredients and improve delivery of poorly soluble drugs.
• Research Focus: Led by Associate Professor Yu-Chi Liu at SERI, with work including diabetic keratopathy and ocular surface inflammation.
• Objective: Aims to enhance bioavailability, efficacy, and safety of topical ocular therapies for clinical application.

This summary is based on a press release issued by Formosa Pharmaceuticals published on The Manila Times.

Image for illustrative purposes only. Source: Canva.